Physician profile
Michelle L Robbins
NPI 1710227244
$2,795.54
in general payments reported to CMS, 2019-2025
22 companies · $690 in 2025
The $690 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $343 · 2023: $403 · 2024: $808 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.20 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $294.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $269.52 | 2023-2025 | |
| Ardelyx, INC. | $247.23 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $239.00 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $187.25 | 2021-2024 | Veltassa |
| Akebia Therapeutics INC | $143.90 | 2022-2024 | Vafseo |
| Alexion Pharmaceuticals, INC. | $137.20 | 2021-2025 | Soliris, Ultomiris |
| Opko Pharmaceuticals, LLC | $131.83 | 2021-2025 | Rayaldee |
| Amgen INC. | $122.11 | 2022-2024 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $76.04 | 2024-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $74.92 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $67.69 | 2021-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.75 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $40.52 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $32.64 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $23.81 | 2024 | Jardiance |
| Travere Therapeutics, INC. | $21.64 | 2025 | |
| Daiichi Sankyo INC. | $21.59 | 2021 | |
| Nxstage Medical, INC. | $20.63 | 2023 | Liberty Select Cycler, Nxstage System One |
| Glaxosmithkline, LLC. | $16.96 | 2025 | Shingrix, Arexvy |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.